Keilholz L, Seegenschmiedt M H, Sauer R
Department of Radiation Oncology, University Erlangen-Nuremberg, Germany.
Int J Radiat Oncol Biol Phys. 1996 Nov 1;36(4):891-7. doi: 10.1016/s0360-3016(96)00421-x.
Radiotherapy (RT) was given to prevent disease progression in early-stage Dupuytren's contracture. Initial response, long-term outcome, and treatment toxicity were evaluated.
Between 1982 and 1993, 96 patients (142 hands) received orthovoltage RT, which consisted of two courses with daily fractionation of 5 x 3 Gy (total dose 30 Gy) separated by a 6-week interval. The extent of disease was staged according to the classification of Tubiana et al.. Initial evaluation was performed 3 months after completion of RT; long-term outcome was analyzed at last follow-up (i.e., between February and April 1994). The mean follow-up was 6 +/- 2 (range 1-12) years. Fifty-seven patients with a minimum follow-up of 5 (median 7.5; mean 9.5-12) years were separately evaluated for long-term outcome (i.e., prevention of disease progression). Acute and late treatment toxicity was assessed using the Radiation Therapy Oncology Group/EORTC criteria.
According to stage, 130 cases (92%) remained stable at 3 months follow-up, 10 improved (7%), and 2 progressed (1%). An objective reduction of symptomatic cords and nodules was achieved in 107 cases (75%) at 3 months follow-up. Moreover, 87% of the patients reported a subjective relief of symptoms. In long-term follow-up, only 16 of 142 cases (11%) had progressed according to stage. In the group with minimum follow-up 5 years (n = 57), 44 patients (77%) experienced no disease progression, whereas 13 progressed (23%) inside [8 cases (14%)] or outside [5 cases (9%)] of the RT field. Most failures could have been avoided with appropriate choice of larger safety margins included in the treated portals; however, the failures outside were still amenable for another RT course.
Radiotherapy is effective to prevent disease progression for early-stage Dupuytren's contracture. Thus, it helps to avoid an otherwise necessary surgical procedure which is performed in adavanced stages of Dupuytren's contracture.
对早期掌腱膜挛缩症患者进行放射治疗(RT)以预防疾病进展。评估初始反应、长期疗效及治疗毒性。
1982年至1993年间,96例患者(142只手)接受了深部X线放疗,包括两个疗程,每日分次剂量为5×3 Gy(总剂量30 Gy),间隔6周。疾病程度根据Tubiana等人的分类进行分期。放疗结束后3个月进行初始评估;在最后一次随访(即1994年2月至4月)时分析长期疗效。平均随访时间为6±2(范围1 - 12)年。对57例最短随访时间为5年(中位数7.5;平均9.5 - 12)的患者单独评估长期疗效(即预防疾病进展)。使用放射治疗肿瘤学组/EORTC标准评估急性和晚期治疗毒性。
根据分期,130例(92%)在3个月随访时病情稳定,10例改善(7%),2例进展(1%)。3个月随访时,107例(75%)有症状的条索和结节客观上有所减少。此外,87%的患者报告症状主观缓解。在长期随访中,142例中只有16例(11%)根据分期出现病情进展。在最短随访5年的组(n = 57)中,44例患者(77%)病情未进展,而13例在放疗野内[8例(14%)]或放疗野外[5例(9%)]出现病情进展。大多数失败情况通过在治疗野中选择更大的安全边界本可避免;然而,放疗野外的失败情况仍可接受另一个放疗疗程。
放射治疗对预防早期掌腱膜挛缩症的疾病进展有效。因此,它有助于避免在掌腱膜挛缩症晚期进行原本必要的外科手术。